Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years (Q54179293)

From Wikidata

Jump to navigation Jump to search

scientific article published on March 1, 1995

Language	Label	Description	Also known as
English	Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years	scientific article published on March 1, 1995

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers a reevaluation after five years (English)

reason for preferred rank

most precise value

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648836

15 July 2024

6

object named as

R N Jones

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

4

object named as

P C Fuchs

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

E. Hugh Gerlach

5

object named as

E H Gerlach

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

author name string

S. A. Marshall

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648836

15 July 2024

K. E. Aldridge

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648836

15 July 2024

S. D. Allen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648836

15 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7648836

15 July 2024

publication date

1 March 1995

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

full work available at URL

https://api.elsevier.com/content/article/PII:0732889395000197?httpAccept=text/xml

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

https://api.elsevier.com/content/article/PII:0732889395000197?httpAccept=text/plain

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

21

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

3

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

153-168

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.

1

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam

3

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers

4

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.

5

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

6

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System

7

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Characterization of beta-lactamases

8

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'.

9

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4.

10

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Kinetic interactions of tazobactam with beta-lactamases from all major structural classes

11

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Multicentre survey of the comparative in-vitro activity of piperacillin/tazobactam against bacteria from hospitalized patients in the British Isles

12

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group

13

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).

14

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli

15

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

More extended-spectrum beta-lactamases

16

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

17

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains

18

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results

19

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.

20

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

21

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria

22

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam

23

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Sur

24

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Tazobactam prevention of emergence of resistance.

29

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections

30

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone

31

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II. Study of the intra- and interlaboratory dissemination of extended-spectrum beta-lactamase-producing Enterobact

33

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection

35

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study

37

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid

38

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia

39

1 reference

10.1016/0732-8893(95)00019-7

https://api.crossref.org/works/10.1016/0732-8893(95)00019-7

15 July 2024

Identifiers

10.1016/0732-8893(95)00019-7

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 May 2018

http://europepmc.org/abstract/MED/7648836

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54179293&oldid=2204700238"